Header and Body 2

Problem Addressed

Patients’ adherence rates to oral therapies taken over an indefinite amount of time are poor, especially for asymptomatic diseases in which the therapy has no noticeable immediate effect. Other factors contributing to poor adherence rates include cost, side effects, accessibility, and the inconvenience of dosing regimens. Current options to increase adherence include the MicroChip device, which requires surgical implantation and is only useful for very potent therapeutics delivered in microgram or smaller quantities. Alternatively, there are orally delivered systems for extended release, but they can only hold at most 1.6 grams of the drug. This technology holds up to 10 grams of active pharmaceutical ingredient, allowing for long-term delivery of a broad range of drugs.